ArticleEuropean radiology2026
MRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR): PART II-Restaging and response evaluation.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- MRI versus histopathology in EMVI detection for rectal cancer: prognostic relevance and survival outcomes.European radiology · 2026Article
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Quantitative MRI T1 relaxation time as a biomarker of complete response in rectal cancer six weeks after neoadjuvant therapy: a prospective study.Clinical and translational radiation oncology · 2026Article
- MRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)-PART I primary staging.European radiology · 2026Article
- Diagnostic Performance and Misclassification Patterns of Preoperative MRI in Rectal Cancer: A Real-World Study.Diagnostics (Basel, Switzerland) · 2026Article
- Early prediction of pathological complete response in rectal cancer: a dynamic immune remodeling hypothesis during neoadjuvant treatment.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo provide up-to-date consensus recommendations on the acquisition, interpretation and reporting of MRI for restaging and response evaluation of rectal cancer after neoadjuvant treatment. MATERIALS AND
methodsA panel of twenty-six abdominal imaging experts from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) participated in an online consensus process, led by three independent non-voting chairs. The process adhered to an adapted version of the RAND-UCLA Appropriateness Method. A total of 126 items were scored (22 general, 55 on primary staging, and 49 on restaging after neoadjuvant treatment), and classified using a cut-off of ≥ 80% to establish consensus.
resultsConsensus was reached for 121 items (96%), from which recommendations regarding hardware, patient preparation, image acquisition protocols, criteria for image interpretation, and MRI reporting were constructed. The current manuscript addresses the results related to restaging after neoadjuvant treatment. Only 1/49 restaging items did not reach consensus. Compared to the previous guideline editions, updated and more detailed recommendations were established on how to assess fibrosis after neoadjuvant therapy, how to restage in the setting of organ preservation, the use of tumour regression grading systems, response assessment in mucinous tumours, evaluation of mesorectal fascia (MRF) involvement and presence of extramural venous invasion (EMVI) after neoadjuvant treatment, and how to deal with nodal response for defining the ycN-category after treatment.
conclusionsThese updated expert consensus recommendations serve as clinical guidelines for the restaging of rectal cancer after neoadjuvant treatment using MRI. Recommendations for primary staging are addressed in a separate publication. KEY POINTS: QuestionSince the last ESGAR rectal imaging guideline update, the rectal cancer treatment landscape has further evolved, necessitating updates to the existing guidelines. FindingsAn online consensus process involving 26 panellists led to 96% consensus across 121 items discussed, including 49 items related to restaging after neoadjuvant treatment. Clinical relevanceKey updates included in these updated guidelines for MRI restaging of rectal cancer include new recommendations for assessing fibrosis, identifying patients for organ preservation, use of tumour regression grading systems, assessing mucinous tumours, ycEMVI, ycMRF, and ycN assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.